A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors

Arinna Bertoni, Sonia Carta, Chiara Baldovini, Federica Penco, Enrica Balza, Silvia Borghini, Marco Di Duca, Emanuela Ognio, Alessio Signori, Paolo Nozza, Francesca Schena, Patrizia Castellani, Claudia Pastorino, Carola Perrone, Laura Obici, Alberto Martini, Isabella Ceccherini, Marco Gattorno, Anna Rubartelli, Sabrina Chiesa

Research output: Contribution to journalArticle

Abstract

Background: Cryopyrin-associated periodic syndromes (CAPS) are a group of autoinflammatory diseases linked to gain-of-function mutations in the NOD-like receptor family, pyrin domain containing 3 (NLRP3) gene, which cause uncontrolled IL-1β secretion. Proton pump inhibitors (PPIs), which are commonly used as inhibitors of gastric acid production, also have anti-inflammatory properties, protect mice from sepsis, and prevent IL-1β secretion by monocytes from patients with CAPS. Objective: We sought to develop a novel Nlrp3 knock-in (KI) mouse model of CAPS to study amyloidosis, a severe CAPS complication, and test novel therapeutic approaches. Methods: We generated KI mice by engineering the N475K mutation, which is associated with the CAPS phenotype, into the mouse Nlrp3 gene. KI and wild-type mice received PPIs or PBS intraperitoneally and were analyzed for survival, inflammation, cytokine secretion, and amyloidosis development. Results: Mutant Nlrp3 KI mice displayed features that recapitulate the immunologic and clinical phenotype of CAPS. They showed systemic inflammation with high levels of serum proinflammatory cytokines, inflammatory infiltrates in various organs, and amyloid deposits in the spleen, liver, and kidneys. Toll-like receptor stimulated macrophages from KI mice secreted high levels of IL-1β, IL-18, and IL-1α but low amounts of IL-1 receptor antagonist. Treatment of KI mice with PPIs had a clear clinical effect, showing a reduction in inflammatory manifestations, regression of amyloid deposits, and normalization of proinflammatory and anti-inflammatory cytokine production by macrophages. Conclusion: Nlrp3 KI mice displayed a CAPS phenotype with many characteristics of autoinflammation, including amyloidosis. The therapeutic effectiveness of PPIs associated with a lack of toxicity indicates that these drugs could represent relevant adjuvants to the anti–IL-1 drugs in patients with CAPS and other IL-1–driven diseases.

Original languageEnglish
JournalJournal of Allergy and Clinical Immunology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Cryopyrin-Associated Periodic Syndromes
Proton Pump Inhibitors
Amyloidosis
Interleukin-1
Amyloid Plaques
Therapeutics
Cytokines
Phenotype
Anti-Inflammatory Agents
Macrophages
Inflammation
Mutation
Interleukin-18
Interleukin-1 Receptors
Mouse Nlrp3 protein
Toll-Like Receptors
Gastric Acid
Drug-Related Side Effects and Adverse Reactions
Genes
Monocytes

Keywords

  • Cryopyrin-associated periodic syndromes
  • IL-1β
  • Nlrp3 mice
  • NOD-like receptor family
  • proton pump inhibitor
  • pyrin domain containing 3

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis : Therapeutic efficacy of proton pump inhibitors. / Bertoni, Arinna; Carta, Sonia; Baldovini, Chiara; Penco, Federica; Balza, Enrica; Borghini, Silvia; Di Duca, Marco; Ognio, Emanuela; Signori, Alessio; Nozza, Paolo; Schena, Francesca; Castellani, Patrizia; Pastorino, Claudia; Perrone, Carola; Obici, Laura; Martini, Alberto; Ceccherini, Isabella; Gattorno, Marco; Rubartelli, Anna; Chiesa, Sabrina.

In: Journal of Allergy and Clinical Immunology, 01.01.2019.

Research output: Contribution to journalArticle

@article{26b31b89c262483e88c706113b19f86f,
title = "A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors",
abstract = "Background: Cryopyrin-associated periodic syndromes (CAPS) are a group of autoinflammatory diseases linked to gain-of-function mutations in the NOD-like receptor family, pyrin domain containing 3 (NLRP3) gene, which cause uncontrolled IL-1β secretion. Proton pump inhibitors (PPIs), which are commonly used as inhibitors of gastric acid production, also have anti-inflammatory properties, protect mice from sepsis, and prevent IL-1β secretion by monocytes from patients with CAPS. Objective: We sought to develop a novel Nlrp3 knock-in (KI) mouse model of CAPS to study amyloidosis, a severe CAPS complication, and test novel therapeutic approaches. Methods: We generated KI mice by engineering the N475K mutation, which is associated with the CAPS phenotype, into the mouse Nlrp3 gene. KI and wild-type mice received PPIs or PBS intraperitoneally and were analyzed for survival, inflammation, cytokine secretion, and amyloidosis development. Results: Mutant Nlrp3 KI mice displayed features that recapitulate the immunologic and clinical phenotype of CAPS. They showed systemic inflammation with high levels of serum proinflammatory cytokines, inflammatory infiltrates in various organs, and amyloid deposits in the spleen, liver, and kidneys. Toll-like receptor stimulated macrophages from KI mice secreted high levels of IL-1β, IL-18, and IL-1α but low amounts of IL-1 receptor antagonist. Treatment of KI mice with PPIs had a clear clinical effect, showing a reduction in inflammatory manifestations, regression of amyloid deposits, and normalization of proinflammatory and anti-inflammatory cytokine production by macrophages. Conclusion: Nlrp3 KI mice displayed a CAPS phenotype with many characteristics of autoinflammation, including amyloidosis. The therapeutic effectiveness of PPIs associated with a lack of toxicity indicates that these drugs could represent relevant adjuvants to the anti–IL-1 drugs in patients with CAPS and other IL-1–driven diseases.",
keywords = "Cryopyrin-associated periodic syndromes, IL-1β, Nlrp3 mice, NOD-like receptor family, proton pump inhibitor, pyrin domain containing 3",
author = "Arinna Bertoni and Sonia Carta and Chiara Baldovini and Federica Penco and Enrica Balza and Silvia Borghini and {Di Duca}, Marco and Emanuela Ognio and Alessio Signori and Paolo Nozza and Francesca Schena and Patrizia Castellani and Claudia Pastorino and Carola Perrone and Laura Obici and Alberto Martini and Isabella Ceccherini and Marco Gattorno and Anna Rubartelli and Sabrina Chiesa",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jaci.2019.05.034",
language = "English",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis

T2 - Therapeutic efficacy of proton pump inhibitors

AU - Bertoni, Arinna

AU - Carta, Sonia

AU - Baldovini, Chiara

AU - Penco, Federica

AU - Balza, Enrica

AU - Borghini, Silvia

AU - Di Duca, Marco

AU - Ognio, Emanuela

AU - Signori, Alessio

AU - Nozza, Paolo

AU - Schena, Francesca

AU - Castellani, Patrizia

AU - Pastorino, Claudia

AU - Perrone, Carola

AU - Obici, Laura

AU - Martini, Alberto

AU - Ceccherini, Isabella

AU - Gattorno, Marco

AU - Rubartelli, Anna

AU - Chiesa, Sabrina

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Cryopyrin-associated periodic syndromes (CAPS) are a group of autoinflammatory diseases linked to gain-of-function mutations in the NOD-like receptor family, pyrin domain containing 3 (NLRP3) gene, which cause uncontrolled IL-1β secretion. Proton pump inhibitors (PPIs), which are commonly used as inhibitors of gastric acid production, also have anti-inflammatory properties, protect mice from sepsis, and prevent IL-1β secretion by monocytes from patients with CAPS. Objective: We sought to develop a novel Nlrp3 knock-in (KI) mouse model of CAPS to study amyloidosis, a severe CAPS complication, and test novel therapeutic approaches. Methods: We generated KI mice by engineering the N475K mutation, which is associated with the CAPS phenotype, into the mouse Nlrp3 gene. KI and wild-type mice received PPIs or PBS intraperitoneally and were analyzed for survival, inflammation, cytokine secretion, and amyloidosis development. Results: Mutant Nlrp3 KI mice displayed features that recapitulate the immunologic and clinical phenotype of CAPS. They showed systemic inflammation with high levels of serum proinflammatory cytokines, inflammatory infiltrates in various organs, and amyloid deposits in the spleen, liver, and kidneys. Toll-like receptor stimulated macrophages from KI mice secreted high levels of IL-1β, IL-18, and IL-1α but low amounts of IL-1 receptor antagonist. Treatment of KI mice with PPIs had a clear clinical effect, showing a reduction in inflammatory manifestations, regression of amyloid deposits, and normalization of proinflammatory and anti-inflammatory cytokine production by macrophages. Conclusion: Nlrp3 KI mice displayed a CAPS phenotype with many characteristics of autoinflammation, including amyloidosis. The therapeutic effectiveness of PPIs associated with a lack of toxicity indicates that these drugs could represent relevant adjuvants to the anti–IL-1 drugs in patients with CAPS and other IL-1–driven diseases.

AB - Background: Cryopyrin-associated periodic syndromes (CAPS) are a group of autoinflammatory diseases linked to gain-of-function mutations in the NOD-like receptor family, pyrin domain containing 3 (NLRP3) gene, which cause uncontrolled IL-1β secretion. Proton pump inhibitors (PPIs), which are commonly used as inhibitors of gastric acid production, also have anti-inflammatory properties, protect mice from sepsis, and prevent IL-1β secretion by monocytes from patients with CAPS. Objective: We sought to develop a novel Nlrp3 knock-in (KI) mouse model of CAPS to study amyloidosis, a severe CAPS complication, and test novel therapeutic approaches. Methods: We generated KI mice by engineering the N475K mutation, which is associated with the CAPS phenotype, into the mouse Nlrp3 gene. KI and wild-type mice received PPIs or PBS intraperitoneally and were analyzed for survival, inflammation, cytokine secretion, and amyloidosis development. Results: Mutant Nlrp3 KI mice displayed features that recapitulate the immunologic and clinical phenotype of CAPS. They showed systemic inflammation with high levels of serum proinflammatory cytokines, inflammatory infiltrates in various organs, and amyloid deposits in the spleen, liver, and kidneys. Toll-like receptor stimulated macrophages from KI mice secreted high levels of IL-1β, IL-18, and IL-1α but low amounts of IL-1 receptor antagonist. Treatment of KI mice with PPIs had a clear clinical effect, showing a reduction in inflammatory manifestations, regression of amyloid deposits, and normalization of proinflammatory and anti-inflammatory cytokine production by macrophages. Conclusion: Nlrp3 KI mice displayed a CAPS phenotype with many characteristics of autoinflammation, including amyloidosis. The therapeutic effectiveness of PPIs associated with a lack of toxicity indicates that these drugs could represent relevant adjuvants to the anti–IL-1 drugs in patients with CAPS and other IL-1–driven diseases.

KW - Cryopyrin-associated periodic syndromes

KW - IL-1β

KW - Nlrp3 mice

KW - NOD-like receptor family

KW - proton pump inhibitor

KW - pyrin domain containing 3

UR - http://www.scopus.com/inward/record.url?scp=85069173958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069173958&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2019.05.034

DO - 10.1016/j.jaci.2019.05.034

M3 - Article

C2 - 31194989

AN - SCOPUS:85069173958

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

ER -